Sterility Testing

Sterility Testing Services for Sterile Products and Devices

Sterility testing is the final compendial check applied to a product that must contain no viable microorganisms at all. It is required for parenteral products, ophthalmic preparations, irrigation solutions, implants, sterile devices and any product labelled sterile, and it is performed under USP <71>, Ph. Eur. 2.6.1 or the corresponding Indian Pharmacopoeia monograph.

DSTechnoverse performs sterility testing by membrane filtration and direct inoculation, with the method suitability and bacteriostasis/fungistasis validation that makes the result meaningful for a specific product. We also support the investigation side, which is where most of the difficulty actually lies: a sterility test positive is one of the most consequential findings in pharmaceutical manufacturing, and how it is handled determines whether the outcome is a contained deviation or a regulatory crisis.

We are explicit with clients about the statistical reality of this test, because it is routinely overstated. Testing twenty units from a batch of fifty thousand detects contamination reliably only when contamination is widespread. If one unit in a thousand is contaminated, a twenty-unit test has roughly a two per cent chance of finding it. The sterility test is a confirmatory check on a validated sterilisation or aseptic process — it is not, and cannot be, the basis on which sterility is assured.

Membrane Filtration vs Direct Inoculation

Two methods are recognised. Membrane filtration is the method of choice wherever the product can be filtered, and using direct inoculation without justification is a common regulatory finding.

• Membrane filtration — the product is passed through a 0.45 µm membrane that retains any organisms, the membrane is rinsed to remove inhibitory residues, then transferred to growth media. Suited to filterable liquids and to large volumes.
• Rinsing is the decisive advantage. Antibiotics, preservatives and other antimicrobial residues are physically washed away from the retained organisms, so inhibition is eliminated rather than merely diluted.
• Entire container contents can be tested by filtration, which substantially improves sensitivity compared with inoculating a small aliquot.
• Direct inoculation — the product is added directly to Fluid Thioglycollate Medium and Soybean Casein Digest Medium. Used for non-filterable products: viscous liquids, ointments, oils, powders that will not dissolve, and solid devices.
• Direct inoculation is constrained by the product-to-medium ratio, typically no more than 10 per cent, which limits the quantity that can be tested and therefore the sensitivity.
• Antimicrobial products tested by direct inoculation require specific neutralisers in the medium, validated to inactivate the product without inhibiting the test organisms.
• Device testing — whole devices are immersed, or product-contacting pathways flushed and the eluate filtered, depending on device geometry and the sterile fluid path definition.

Method Suitability and Bacteriostasis/Fungistasis Validation

A sterility result is only valid if the method has been shown to detect low numbers of organisms in the presence of your product. For each product we run the bacteriostasis and fungistasis study with the compendial challenge organisms at fewer than 100 CFU. Where the product inhibits growth we adapt the method — more rinses, validated neutralisers or a larger medium volume — until suitability is demonstrated.

The validated method becomes your routine procedure and is revalidated whenever the formulation, container, filters or media supplier change. Our guide to sterility testing under USP <71> covers the study design in detail.

How Each Test Is Controlled

• Both compendial media — fluid thioglycollate and soybean-casein digest — incubated at their specified temperatures for the full 14 days.
• Growth promotion testing of every media lot before use.
• Negative and filtration controls in every session, to detect contamination introduced by the test itself.
• Testing in a Grade A environment with environmental monitoring running during the session.
• Analysts qualified by simulating the sterility test procedure, and requalified periodically.

Sample Numbers and What They Actually Prove

The pharmacopoeias specify minimum sample numbers by batch size and container volume — typically 20 units for a batch above 500 containers, and 10 per cent or 4 containers, whichever is greater, for smaller batches. These numbers are compendial minimums, not statistical guarantees.

The mathematics are worth stating plainly because they drive how the result should be used. With 20 units tested, a contamination rate of 10 per cent is detected with about 88 per cent probability; a rate of 1 per cent with about 18 per cent probability; and a rate of 0.1 per cent with about 2 per cent probability. Low-level sporadic contamination — precisely the kind that arises from an intermittent aseptic breach — is very likely to pass.

This is why sterility assurance is built from sterilisation validation, aseptic process simulation (media fills), environmental monitoring, bioburden control and container closure integrity, with the sterility test as the last confirmatory step rather than the foundation. Any manufacturer whose sterility argument rests primarily on the sterility test has a fragile position.

Handling a Sterility Test Positive

A positive sterility test triggers one of the most heavily scrutinised investigations in pharmaceutical manufacturing. The compendia permit invalidation of the test only where it can be demonstrated that the growth resulted from a fault in the test itself — not from a general belief that laboratory contamination is likely.

1. 1Preserve and identify the isolate immediately. The species is the single most informative piece of evidence and everything downstream depends on it.
2. 2Review the test session records — environmental monitoring during the session, operator gowning and glove prints, isolator or LAF integrity, media growth promotion and sterility, filtration controls and any recorded deviation.
3. 3Assess whether the organism is consistent with laboratory origin. A common skin organism recovered alongside a failed operator glove print is a very different case from a water organism recovered with all controls valid.
4. 4Extend to the manufacturing investigation if no test fault is established. Review the batch record, sterilisation records, filter integrity test results, aseptic interventions, media fill history and environmental data for the production period.
5. 5Type the isolate against the facility flora library and against any contamination investigation isolates, to establish whether a route exists.
6. 6Assess the batch and any related batches. Sterilisation load records, campaign structure and shared equipment determine the scope.
7. 7Reach a documented conclusion. Invalidation requires evidence of a specific test fault; absent that, the batch fails and the investigation extends to manufacturing.
8. 8Implement corrective action and verify effectiveness through intensified monitoring and, where appropriate, an additional media fill.

What Sterility Assurance Actually Rests On

Because the sterility test itself is statistically weak, the real assurance comes from a set of controls that operate before the test. A regulator assessing a sterility claim examines these, and finding them weak is far more damaging than a single positive result.

• Sterilisation validation — a demonstrated lethality delivering a Sterility Assurance Level of 10⁻⁶ for terminally sterilised product, with cycle parameters proven across the load configurations actually used.
• Pre-sterilisation bioburden control — a known, monitored and stable microbial load, since the validated cycle was designed against a specific starting population.
• Aseptic process simulation — media fills at defined frequency covering worst-case interventions, shift patterns, line speeds and campaign durations, with a contamination rate target of zero.
• Filter integrity testing — pre-use and post-use bubble point or diffusion testing on sterilising-grade filters, with the post-use test being the one that actually protects the batch.
• Container closure integrity — demonstrated by a validated physical method rather than by dye ingress alone, across the shelf life and any transport or temperature stress.
• Environmental monitoring — a Grade A zone with a demonstrated record of no recovery, supported by Grade B background data.
• Personnel qualification — gowning qualification, aseptic technique assessment and glove print monitoring for every operator entering the critical zone.
• Interventions — every routine and non-routine intervention defined, risk-assessed and covered by media fill, since unplanned interventions are the dominant cause of aseptic contamination.

Rapid Sterility Testing

The 14-day incubation is a significant commercial constraint, particularly for short-shelf-life products, radiopharmaceuticals and cell and gene therapies where the product may expire before a conventional result exists.

Validated rapid methods can reduce time to result substantially — respiration-based systems, ATP bioluminescence, solid-phase cytometry and nucleic acid amplification approaches typically report within 5 to 7 days, and some considerably faster. The regulatory price of admission is a full equivalence validation demonstrating that the alternative method is at least as sensitive as the compendial one, across the relevant organism range and in the specific product matrix.

We advise on whether the business case justifies that validation effort. For a high-volume product with significant working capital tied up in quarantine, it frequently does. For an occasional batch, it rarely does.

How DSTechnoverse Helps

• Method suitability and bacteriostasis/fungistasis validation for each product and container configuration.
• Routine sterility testing by membrane filtration or direct inoculation under USP <71>, Ph. Eur. 2.6.1 and IP.
• Medical device sterility testing under the ISO 11737-2 approach, including fluid path flushing and whole-device immersion.
• Concurrent environmental monitoring of the test session, so a positive result can be assessed against the conditions under which it arose.
• Positive-result investigation — isolate identification, strain typing, session review and structured root cause work.
• Sterility assurance review — assessing whether your sterilisation validation, media fills, bioburden control and environmental programme actually support the sterility claim the test is being asked to confirm.
• Rapid method evaluation and equivalence validation where faster release has a demonstrable commercial case.
• Regulatory documentation — validation packages, investigation reports and audit support for CDSCO and export markets.

Get Sterility Testing With the Validation Behind It

If you need sterility testing, the first question we will ask is not about the test but about the suitability validation and what your sterility assurance rests on. Both determine whether the result will hold up.

DSTechnoverse is based in **Indore** and provides sterility testing support to sterile manufacturers across India. Given the 14-day incubation, sample logistics matter less than testing quality here — clients nationwide ship to our facility without any turnaround penalty.

Contact DSTechnoverse to discuss sterility testing, or review the upstream control in bioburden testing.

Frequently Asked Questions

Guides and Resources

• Same-day sample collection for units in Pithampur, Dewas and Mandideep →